Papillary thyroid cancer (PTC) is the most common thyroid malignancy worldwide, representing approximately 85% of all thyroid cancer diagnoses. While it carries an excellent overall prognosis, achieving the best outcomes requires precise surgical technique, appropriate surgical extent, and meticulous preservation of the recurrent laryngeal nerves and parathyroid glands. At THANC Hospital in Chennai, Dr. Vidhyadharan Sivakumar performs papillary thyroid cancer surgery using Intraoperative Nerve Monitoring (IONM) as standard practice, drawing on his MCh in Head & Neck Surgery, FEB-ORL HNS (European Board certification), FICRS, Gold Medal in MS (ENT), and over 3000 head and neck surgeries to deliver outcomes that prioritise both cancer clearance and functional preservation.
Understanding Papillary Thyroid Cancer
The thyroid gland is a butterfly-shaped endocrine organ located in the front of the neck, just below the Adam's apple. It produces thyroid hormones (T3 and T4) that regulate metabolism, heart rate, body temperature, and numerous physiological functions. Papillary thyroid cancer arises from the follicular epithelial cells of the thyroid gland but grows in a characteristic papillary (finger-like projection) pattern that gives this cancer its name.
PTC typically presents as a slow-growing, painless thyroid nodule. In India, the incidence has been steadily rising, partly due to increased detection through widespread ultrasound use. Chennai receives a significant volume of thyroid cancer referrals from across Tamil Nadu, Andhra Pradesh, Karnataka, and Kerala.
PTC affects women approximately three times more frequently than men, with peak incidence between ages 30 and 50. Despite its classification as cancer, PTC has a remarkably favourable prognosis -- 10-year disease-specific survival exceeds 98% for patients under 55 without distant metastases. This favourable biology does not diminish the importance of expert surgical management, as the quality of the initial surgery directly impacts recurrence rates and long-term quality of life.
Understanding the broader context of thyroid nodules and when they require concern is essential for patients navigating a new thyroid cancer diagnosis. Not every nodule is cancer, but every thyroid cancer starts as a nodule -- distinguishing the two requires a systematic diagnostic approach.
Types and Classification
Not all papillary thyroid cancers behave identically. The WHO classification recognises several histological variants with distinct prognostic implications:
Classic PTC is the most common subtype, characterised by papillary architecture and distinctive nuclear features (ground-glass nuclei, nuclear grooves, pseudoinclusions). It carries an excellent prognosis with standard treatment.
Follicular variant of PTC (FVPTC) is the second most common variant, now subdivided into infiltrative and encapsulated forms. The encapsulated non-invasive form has been reclassified as "Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features" (NIFTP) -- a non-malignant entity that requires lobectomy alone, not cancer treatment.
Tall cell variant is more aggressive than classic PTC, with higher rates of extrathyroidal extension, lymph node metastases, and radioactive iodine refractoriness. It requires more aggressive initial treatment including total thyroidectomy and consideration of radioactive iodine.
Diffuse sclerosing variant is more common in younger patients, characterised by diffuse involvement of the thyroid gland, extensive lymph node metastases, and higher recurrence rates despite generally favourable survival.
Columnar cell and hobnail variants are rare but aggressive subtypes with poorer prognosis requiring comprehensive multimodal treatment.
Identifying the specific variant is critical to surgical planning, and Dr. Vidhyadharan integrates histological subtype data into his decision-making regarding the extent of thyroidectomy, the need for neck dissection, and postoperative radioactive iodine therapy.
Causes and Risk Factors
Several factors increase the risk of developing papillary thyroid cancer:
- Radiation exposure: Prior head and neck radiation, particularly during childhood, is the most well-established risk factor.
- Family history: Approximately 5-10% of PTC cases are familial. First-degree relatives carry a 4-10 fold increased risk.
- Genetic mutations: BRAF V600E mutation (present in 45-60% of PTCs) is associated with more aggressive behaviour. RAS mutations and RET/PTC rearrangements are other drivers.
- Iodine status: Adequate iodine intake is associated with a higher proportion of papillary thyroid cancers.
- Hashimoto's thyroiditis: May slightly increase PTC risk, though coexisting Hashimoto's is associated with more favourable prognosis.
- Obesity and metabolic syndrome: Emerging evidence links insulin resistance with increased risk.
- Female sex: The 3:1 female predominance suggests a hormonal component.
Signs and Symptoms
The majority of papillary thyroid cancers present with few or no symptoms:
- Thyroid nodule: A firm, painless lump in the front of the neck is the most common presentation. Many nodules are discovered incidentally during imaging for unrelated conditions.
- Cervical lymphadenopathy: Enlarged lymph nodes in the lateral neck or central compartment may be the first clinical sign, sometimes even before the primary thyroid nodule is palpable.
- Voice changes: Hoarseness or a breathy voice may indicate involvement of the recurrent laryngeal nerve by an advanced tumour and warrants urgent evaluation.
- Dysphagia and neck pressure: Difficulty swallowing can occur with larger tumours or those with extrathyroidal extension.
- Incidental detection: An increasing proportion of PTCs are detected as incidental findings on imaging studies -- these "incidentalomas" present a clinical challenge in determining which nodules require intervention.
Any thyroid nodule that is firm, growing, associated with hoarseness, or accompanied by neck lymph node enlargement should be evaluated promptly by a head and neck surgical oncologist.
Diagnosis at THANC Hospital
Dr. Vidhyadharan employs a systematic, evidence-based diagnostic approach for suspected papillary thyroid cancer at THANC Hospital in Chennai.
High-resolution neck ultrasound is the cornerstone of thyroid nodule assessment. Features suggesting malignancy include solid hypoechoic composition, irregular or microlobulated margins, microcalcifications, taller-than-wide shape, and suspicious cervical lymph nodes. The ACR TI-RADS scoring system standardises nodule assessment and guides the decision for biopsy.
Ultrasound-guided FNAC is the gold standard for evaluating thyroid nodules. The Bethesda System for Reporting Thyroid Cytopathology categorises results into six categories:
| Bethesda Category | Interpretation | Risk of Malignancy | Recommended Action |
|---|---|---|---|
| I -- Non-diagnostic | Insufficient sample | 5-10% | Repeat FNAC |
| II -- Benign | Benign nodule | 0-3% | Follow-up ultrasound |
| III -- Atypia of Undetermined Significance | Indeterminate | 10-30% | Repeat FNAC, molecular testing, or lobectomy |
| IV -- Follicular Neoplasm | Indeterminate | 25-40% | Lobectomy (diagnostic surgery) |
| V -- Suspicious for Malignancy | Likely PTC | 50-75% | Lobectomy or total thyroidectomy |
| VI -- Malignant | Confirmed PTC | 97-99% | Surgery (lobectomy or total thyroidectomy) |
Preoperative staging includes comprehensive neck ultrasound mapping of the central and lateral compartments, flexible laryngoscopy to document vocal cord function, and cross-sectional imaging (CT or MRI) for locally advanced tumours. Blood investigations include TSH, free T4, thyroglobulin (baseline), anti-thyroglobulin antibodies, calcium, and vitamin D levels.
For patients seeking a comprehensive understanding of the surgical journey, the guide on thyroid cancer surgery provides detailed preparation information.
How Dr. Vidhyadharan Treats Papillary Thyroid Cancer
At THANC Hospital, Dr. Vidhyadharan performs papillary thyroid cancer surgery tailored to the ATA (American Thyroid Association) risk stratification and individual patient factors. His approach combines oncological completeness with meticulous functional preservation, informed by training across 8 countries and over 3000 head and neck surgeries.
Extent of Thyroidectomy
Total thyroidectomy (removal of both thyroid lobes and isthmus) is recommended for tumours larger than 4 cm, bilateral thyroid disease, extrathyroidal extension, clinically apparent lymph node metastases (cN1), aggressive histological variants (tall cell, diffuse sclerosing, columnar cell), when radioactive iodine therapy is planned, and in patients with a history of head and neck radiation.
Thyroid lobectomy (removal of one thyroid lobe with isthmus) is appropriate for unifocal tumours 1-4 cm confined to one lobe without extrathyroidal extension, with no clinical evidence of lymph node metastases, classic PTC or follicular variant histology, and when the patient prefers a less extensive surgery after informed discussion.
The global trend in thyroid cancer surgery has shifted toward more selective use of total thyroidectomy, recognising that lobectomy provides equivalent survival for appropriately selected low-risk tumours while avoiding the need for lifelong complete thyroid hormone replacement.
Lymph Node Management
Papillary thyroid cancer frequently involves cervical lymph nodes. Dr. Vidhyadharan performs compartment-oriented neck dissection rather than "berry picking" individual nodes, ensuring complete oncological clearance. Prophylactic central neck dissection (Level VI) is performed during total thyroidectomy for tumours larger than 4 cm or with extrathyroidal extension. Therapeutic central and lateral neck dissection (Levels II-V) is performed when lymph node metastases are confirmed preoperatively on ultrasound and FNAC.
IONM Nerve Monitoring: The Safety Standard
The recurrent laryngeal nerves control vocal cord movement and voice production. Injury to these nerves during thyroidectomy can cause hoarseness, breathy voice, or airway compromise. Dr. Vidhyadharan uses Intraoperative Nerve Monitoring (IONM) as a routine adjunct during every thyroid cancer surgery at THANC Hospital -- not limited to select cases.
IONM works by placing electrodes on the vocal cords via the endotracheal tube. A stimulation probe identifies and maps the recurrent laryngeal nerve during surgery, providing real-time auditory and visual feedback confirming nerve integrity. Key advantages include nerve identification in revision surgeries or distorted anatomy, functional confirmation at the end of dissection, and staged surgery planning if signal loss occurs on one side during total thyroidectomy to prevent bilateral nerve injury.
Lobectomy vs. Total Thyroidectomy: Comparison
| Parameter | Thyroid Lobectomy | Total Thyroidectomy |
|---|---|---|
| Indication | Low-risk PTC, 1-4 cm, unifocal, cN0 | High-risk PTC, >4 cm, bilateral, cN1, aggressive variant |
| Thyroid hormone replacement | May not be needed (50-80% maintain normal function) | Lifelong levothyroxine required |
| RAI eligibility | Not applicable | Eligible for RAI when indicated |
| Thyroglobulin monitoring | Less reliable (remaining thyroid tissue produces Tg) | Highly reliable surveillance marker |
| Hypoparathyroidism risk | Very low (<1%) | 1-5% temporary; <1% permanent |
| RLN injury risk | <1% with IONM | 1-2%; mitigated by IONM |
| Hospital stay | 1 day | 1-2 days |
| Recurrence rate | 1-4% (appropriately selected low-risk) | 1-3% |
| 10-year survival | >98% | >98% |
Radioactive Iodine and TSH Suppression
After total thyroidectomy, radioactive iodine (RAI) therapy is considered based on risk stratification. Low-risk patients generally do not need RAI, intermediate-risk patients receive selective RAI, and high-risk patients with gross extrathyroidal extension, large lymph node metastases, or distant disease receive routine RAI. All patients receive levothyroxine with TSH suppression levels calibrated to their risk category -- from <0.1 mIU/L for high-risk to near-normal 0.5-2.0 mIU/L for low-risk patients after initial treatment.
What to Expect: Your Treatment Journey
At THANC Hospital, Dr. Vidhyadharan guides patients through a structured treatment pathway designed for both clinical excellence and patient comfort.
Before surgery, the preoperative visit includes thorough clinical examination, review of ultrasound and cytology reports, flexible laryngoscopy, and blood investigations. Dr. Vidhyadharan discusses the planned surgery, expected outcomes, potential complications, and the rationale for the recommended extent. Preoperative anaesthesia assessment and any necessary optimisation (calcium, vitamin D supplementation, thyroid function control) are completed.
Day of surgery, thyroidectomy is performed under general anaesthesia through a cosmetic collar incision (3-5 cm, placed in a natural skin crease). Surgery duration is typically 1.5 to 3 hours depending on the extent of thyroidectomy and whether neck dissection is included. IONM is set up before the first incision and monitors nerve function throughout the procedure.
After surgery, pain is typically mild and well controlled. Voice is assessed within hours. After total thyroidectomy, calcium levels are monitored every 6-12 hours. Oral diet resumes within hours, and most patients are discharged on postoperative day 1. Wound review occurs at 1-2 weeks. Final histopathology results are reviewed at 4-6 weeks, at which point risk stratification is completed and the multidisciplinary tumour board determines whether radioactive iodine is indicated.
Understanding what to expect during thyroidectomy recovery helps patients prepare physically and mentally for the postoperative period.
Recovery and Rehabilitation
Recovery after thyroidectomy for papillary thyroid cancer is generally straightforward. Most patients return to sedentary work within 1-2 weeks and full physical activity within 3-4 weeks. The neck incision matures over 6-12 months, typically fading to a barely visible line.
Thyroid hormone replacement is initiated after total thyroidectomy, adjusted at 6-8 week intervals until stable. After lobectomy, approximately 50-80% maintain adequate thyroid function.
Calcium management addresses temporary hypoparathyroidism (5-15% after total thyroidectomy) with calcium and vitamin D supplementation, gradually tapered as parathyroid function recovers.
Voice preservation is supported by routine IONM use. Any voice changes are assessed with laryngoscopy and managed with speech therapy if needed.
Long-term follow-up continues for at least 10 years: neck ultrasound every 6-12 months for the first 5 years then annually, thyroglobulin and anti-thyroglobulin antibody monitoring, TSH checks, and stimulated thyroglobulin testing at 9-12 months post-treatment.
Outcomes and Prognosis
Papillary thyroid cancer is among the most curable of all cancers. The staging system for differentiated thyroid cancer uniquely incorporates patient age:
- Stage I (patients under 55): Encompasses all PTC without distant metastases. 10-year survival exceeds 99%.
- Stage II (patients under 55): PTC with distant metastases. 10-year survival approximately 85%.
- Stage I (patients 55 and older): Small tumours confined to the thyroid without lymph node metastases. 10-year survival exceeds 98%.
- Stage II (patients 55 and older): Larger tumours or with lymph node metastases. 10-year survival approximately 90%.
- Stage III-IV (patients 55 and older): Gross extrathyroidal extension or distant metastases. Survival depends on extent and response to treatment.
Recurrence rates are approximately 5-15% over 10 years, most commonly in cervical lymph nodes, and recurrent disease is usually treatable with surgery or radioactive iodine with excellent salvage outcomes. The vast majority of PTC patients treated at THANC Hospital fall into low or intermediate risk categories and can expect excellent long-term outcomes.
Why Choose Dr. Vidhyadharan at THANC Hospital
Choosing the right surgeon for papillary thyroid cancer directly impacts recurrence rates, nerve preservation, and long-term quality of life. Dr. Vidhyadharan Sivakumar offers a combination of qualifications, experience, and technology that distinguishes his practice:
- MCh (Head & Neck Surgery) from Amrita Institute -- super-speciality training in oncological thyroid surgery.
- Gold Medal in MS (ENT) from Annamalai University -- foundational excellence in head and neck surgical anatomy.
- FEB-ORL HNS (European Board certification) -- the highest European qualification in head and neck surgery.
- FICRS (robotic surgery certification) -- fellowship at Royal Adelaide Hospital, Australia.
- Over 3000 head and neck surgeries -- extensive operative experience spanning thyroid cancer, neck dissection, and complex revision procedures.
- Routine IONM nerve monitoring -- standard for every thyroid cancer surgery, not limited to select cases.
- Training across 8 countries -- including microsurgery at Chang Gung Memorial Hospital Taiwan, skull base surgery at Toronto General Hospital Canada, and the ASOHNS fellowship at Royal Adelaide Hospital Australia.
- Evidence-based decision-making -- surgical extent tailored to ATA risk stratification, avoiding both under-treatment and over-treatment.
- Multidisciplinary tumour board at THANC Hospital with nuclear medicine, radiation oncology, medical oncology, pathology, and endocrinology.
For a personalised assessment and treatment plan, schedule a consultation with Dr. Vidhyadharan Sivakumar at THANC Hospital, Kilpauk, Chennai.
Phone: +91 73059 53378 Location: THANC Hospital, 747 Poonamallee High Road, Kilpauk, Chennai 600010 Book an Appointment
